Aarti Pharmalabs Ltd Stock Price Today (NSE: AARTIPHARM)
Fundamental Score
Aarti Pharmalabs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Aarti Pharmalabs Ltd share price today is ₹648.20, up +1.38% on NSE/BSE as of 17 June 2026. Aarti Pharmalabs Ltd (AARTIPHARM) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹6.37K (Cr). The 52-week high for AARTIPHARM share price is ₹971.00 and the 52-week low is ₹585.00. At a P/E ratio of 26.57x, AARTIPHARM is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 14.54% and a debt-to-equity ratio of 0.32.
Aarti Pharmalabs Ltd Share Price Chart — NSE/BSE Historical Performance
Aarti Pharmalabs Ltd share price chart: -7.14% return over the past month. 52-week high ₹971.00, 52-week low ₹585.00.
Aarti Pharmalabs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹642.35 | ₹646.90 | ₹628.15 | ₹635.20 | 1.72L (Cr) | |
| ₹635.00 | ₹659.70 | ₹635.00 | ₹642.35 | 2.00L (Cr) | |
| ₹656.25 | ₹663.00 | ₹626.00 | ₹633.25 | 5.04L (Cr) | |
| ₹694.60 | ₹700.00 | ₹652.50 | ₹655.25 | 5.27L (Cr) | |
| ₹706.80 | ₹720.00 | ₹691.25 | ₹694.60 | 5.04L (Cr) | |
| ₹714.15 | ₹741.40 | ₹714.15 | ₹732.45 | 1.61L (Cr) | |
| ₹703.50 | ₹727.25 | ₹702.65 | ₹713.10 | 1.28L (Cr) | |
| ₹710.80 | ₹711.40 | ₹701.00 | ₹703.50 | 78.24K (Cr) | |
| ₹700.45 | ₹709.70 | ₹698.10 | ₹700.75 | 1.08L (Cr) | |
| ₹701.00 | ₹718.65 | ₹697.20 | ₹705.90 | 77.87K (Cr) |
Aarti Pharmalabs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹635.00 | ₹659.70 | ₹628.15 | ₹635.20 | +0.03% | |
| ₹751.35 | ₹814.00 | ₹626.00 | ₹633.25 | -15.72% | |
| ₹610.00 | ₹753.40 | ₹610.00 | ₹740.25 | +21.35% | |
| ₹681.00 | ₹714.95 | ₹585.00 | ₹591.95 | -13.08% | |
| ₹737.20 | ₹803.50 | ₹678.60 | ₹723.70 | -1.83% | |
| ₹752.40 | ₹817.90 | ₹723.15 | ₹753.20 | +0.11% | |
| ₹697.10 | ₹784.25 | ₹685.30 | ₹752.40 | +7.93% | |
| ₹847.70 | ₹869.85 | ₹672.70 | ₹700.65 | -17.35% | |
| ₹828.50 | ₹875.00 | ₹820.00 | ₹851.95 | +2.83% | |
| ₹847.00 | ₹946.10 | ₹802.85 | ₹827.65 | -2.28% | |
| ₹911.20 | ₹918.35 | ₹740.80 | ₹841.35 | -7.67% | |
| ₹898.30 | ₹971.00 | ₹884.85 | ₹911.20 | +1.44% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Aarti Pharmalabs is a volatile bet on API backward integration and CDMO ramp-up, overshadowed by promoter actions and margin risks.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Aarti Pharmalabs closed its trading window on April 1, 2026, in anticipation of its FY26 financial results. The board meeting date to approve these results is yet to be announced. Promoter Mirik Rajendra Gogri made disclosures regarding substantial acquisition of shares on April 2, 2026. The company also addressed a delay in regulatory disclosure and a penalty of s from CGST and Central Excise authority.
CORE STORY (THE REAL GAME)
Aarti Pharmalabs is being priced as a backward integration play in the API space, with a potential kicker from its CDMO business. The market is watching to see if they can successfully ramp up the Atali plant and capitalize on the shift towards domestic API production.
- API backward integration narrative gaining traction
- CDMO plant operational and expected to ramp up
- Government push for domestic pharma manufacturing
- Successful CDMO ramp-up with new client wins
- API margin expansion due to backward integration
- Positive regulatory developments for domestic API production
- Promoter pledging of shares
- API margin volatility and customer inventory buildup
- Micro-cap liquidity risk
FII increased stake by 0.68%, while DII decreased stake by 0.85% [cite: brief]. Promoter decreased stake by 0.84% [cite: brief].
Indian pharma sector benefiting from government support and a global shift towards supply chain diversification.
Poor: Negative free cash flow of ₹-149.15 Cr over the last 5 years [cite: brief].
Aarti Pharmalabs' success hinges on its ability to execute its CDMO strategy and improve API margins. Expect volatility in the next 3-6 months as the market assesses its progress.
Primary Thesis Risk
Failure to improve API margins and successfully ramp up the CDMO business will crush the thesis.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Aarti Pharmalabs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aarti Pharmalabs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AARTIPHARM across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Excellent ROCE Performance (17.44%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Interest Coverage (10.39x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Risk Factors
3 factors identified
Profit Decline Concern (-48.88%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-8.67%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Negative Free Cash Flow (₹-149.15 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Aarti Pharmalabs Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Aarti Pharmalabs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Aarti Pharmalabs LtdAarti Pharmalab...Selected✓ AARTIPHARM • 543748 | 23.7/100 | ₹648.20₹648 | ₹6371.15₹6371.15 | 26.57Average 26.6 Average | 14.54%Average 14.54% Average | 17.44%Good 17.44% Good | 0.32Excellent 0.3 Excellent | — — | — — | 0.71% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Aarti Pharmalabs Ltd PE Ratio History
Historical price-to-earnings ratio for AARTIPHARM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹30.04 | ₹752.40 | 25x |
| FY 2024 | ₹23.93 | ₹686.25 | 28.7x |
| FY 2023 | ₹21.35 | ₹504.45 | 23.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Aarti Pharmalabs Ltd Dividend History
Annual cash dividends paid by AARTIPHARM — dividend yield 0.71%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹31.72 Cr |
| FY 2024 | ₹18.13 Cr |
| FY 2023 | ₹18.13 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Aarti Pharmalabs Ltd Quarterly Performance
Latest quarterly metrics for AARTIPHARM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-8.67%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-48.88%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Aarti Pharmalabs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AARTIPHARM — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Aarti Pharmalabs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Aarti Pharmalabs Ltd (AARTIPHARM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Aarti Pharmalabs Ltd
About AARTIPHARM (Aarti Pharmalabs Ltd)
Aarti Pharmalabs Ltd is a dynamic force within the global pharmaceutical arena, a company deeply rooted in innovation and dedicated to the development, production, and distribution... of high-quality pharmaceutical solutions. Focused on manufacturing excellence, they specialize in a diverse portfolio of Active Pharmaceutical Ingredients (APIs) and advanced pharmaceutical intermediates, serving as a crucial partner for pharmaceutical companies worldwide. Their commitment to stringent quality control measures, coupled with state-of-the-art manufacturing facilities, ensures that they consistently meet and exceed the exacting standards of the industry. This dedication extends beyond product quality, encompassing a strong emphasis on environmental responsibility and sustainable manufacturing practices. The company's comprehensive product range caters to a multitude of therapeutic areas, reflecting their ambition to contribute meaningfully to global healthcare needs. From complex chemical syntheses to the efficient scaling of production processes, Aarti Pharmalabs demonstrates expertise in every facet of pharmaceutical development. They leverage advanced technologies and a highly skilled workforce to deliver cost-effective and reliable solutions to their clients. Moreover, their active pursuit of research and development allows them to remain at the forefront of pharmaceutical advancements, constantly exploring new molecules and innovative manufacturing techniques. Their commitment to backward integration strengthens their supply chain. Aarti Pharmalabs Ltd has established a strong international presence. Their global reach and adherence to international regulatory standards reinforces their position as a trusted supplier in the pharmaceutical landscape. Through strategic collaborations and a customer-centric approach, they build lasting relationships with pharmaceutical companies across continents. By continuously investing in their infrastructure and talent pool, Aarti Pharmalabs positions itself for sustained growth and continued success in the ever-evolving pharmaceutical industry. With a firm focus on innovation, quality, and sustainability, Aarti Pharmalabs is working to become a trusted partner to its customers.
Company Details
Key Leadership
Corporate Events
AARTIPHARM Share Price: Frequently Asked Questions
What is the current share price of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd (AARTIPHARM) trades at ₹648.20 on NSE and BSE. Market cap ₹6.37K (Cr). Educational data only.
What is the P/E ratio of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd has a P/E of 26.57x vs industry average 31.77x.
What is the Bull Run score for Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd has a Bull Run score of 23.7/100 based on 25+ financial parameters.
Does Aarti Pharmalabs Ltd pay dividends?
Aarti Pharmalabs Ltd has a dividend yield of 0.71%. Past dividends don't guarantee future payments.
What is the ROE of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd has ROE of 14.54%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd has debt-to-equity of 0.32.
Is Aarti Pharmalabs Ltd a good investment?
Bull Run gives Aarti Pharmalabs Ltd a score of 23.7/100. This is not investment advice — consult a SEBI-registered advisor.